Large-Scale Identification and Analysis of Suppressive Drug Interactions  by Cokol, Murat et al.
Chemistry & Biology
ArticleLarge-Scale Identification and Analysis
of Suppressive Drug Interactions
Murat Cokol,1,2,11,* Zohar B. Weinstein,1,3 Kaan Yilancioglu,1,3 Murat Tasan,3 Allison Doak,4 Dilay Cansever,1,3
Beste Mutlu,1,3 Siyang Li,3 Raul Rodriguez-Esteban,5 Murodzhon Akhmedov,1 Aysegul Guvenek,1 Melike Cokol,1
Selim Cetiner,1 Guri Giaever,3,6 Ivan Iossifov,7 Corey Nislow,3,6 Brian Shoichet,4 and Frederick P. Roth3,8,9,10,11,*
1Biological Sciences and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey
2Nanotechnology Research and Application Center, Sabanci University, Istanbul 34956, Turkey
3Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada
4Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA
5Department of Computational Biology, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT 06877, USA
6Department of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada
7Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
8Center for Cancer Systems Biology, Dana-Farber Cancer Institute, One Jimmy Fund Way, Boston, MA 02215, USA
9Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON M5G 1X5, Canada
10Departments of Molecular Genetics and Computer Science, University of Toronto, Toronto, ON M5S 3E1, Canada
11These authors contributed equally to this work and are co-senior authors
*Correspondence: cokol@sabanciuniv.edu (M.C.), fritz.roth@utoronto.ca (F.P.R.)
http://dx.doi.org/10.1016/j.chembiol.2014.02.012SUMMARY
One drug may suppress the effects of another.
Although knowledge of drug suppression is vital to
avoid efficacy-reducing drug interactions or discover
countermeasures for chemical toxins, drug-drug
suppression relationships have not been systemati-
cally mapped. Here, we analyze the growth response
of Saccharomyces cerevisiae to anti-fungal com-
pound (‘‘drug’’) pairs. Among 440 ordered drug pairs,
we identified 94 suppressive drug interactions. Using
only pairs not selected on the basis of their sup-
pression behavior, we provide an estimate of the
prevalence of suppressive interactions between
anti-fungal compounds as 17%. Analysis of the drug
suppression network suggested that Bromopyruvate
is a frequently suppressive drug and Staurosporine
is a frequently suppressed drug. We investigated
potential explanations for suppressive drug inter-
actions, including chemogenomic analysis, coaggre-
gation, and pH effects, allowing us to explain the
interaction tendencies of Bromopyruvate.
INTRODUCTION
Drugs are considered to be interacting if their combined effect
for a particular phenotype differs from the independently com-
bined single-drug effects. Interactions are considered syner-
gistic if they correspond to a more severe combined effect or
antagonistic for a diminished combinatorial effect. Suppression
or hyperantagonism is an extreme case of drug antagonism,
defined by an effect of the drug combination that is less than
the effect of the more-potent drug alone (Figure 1) (Yeh et al.,
2009). Cases of suppression in vivo are well known and mayChemistry & Biology 21,arise from a variety of mechanisms, including changes in meta-
bolism, absorption, and excretion (Fugh-Berman, 2000; Patsalos
and Perucca, 2003).
Numerous studies have been conducted to seek synergistic
drug combinations for their enhanced therapeutic value (Farha
and Brown, 2010; Leha´r et al., 2009). However, it is also impor-
tant to identify those combinations in which one drug sup-
presses the effect of the other. For example, the standard
dose of Rapamycin (Rap) must be increased by a factor of
300 to restore its effects on T-lymphocytes due to the suppres-
sive effects of Tacrolimus (Tac) (FK506) (Bierer et al., 1990).
Numerous examples of Rap being suppressed are known. For
example, case studies on organ transplant patients report
the effects of Rap to be suppressed by coadministration of
Phenytoin (Fridell et al., 2003) or Rifampacin (Ngo et al., 2011).
Few drug suppression relationships have been mechanisti-
cally explained. In one example, a recent study showed that
protein synthesis inhibitors suppress DNA synthesis inhibitors
in Escherichia coli, because of non-optimal regulation of ribo-
somal genes in the presence of DNA stress (Bollenbach et al.,
2009). It is clear that this mechanism can explain only a small
subset of all suppressive drug interactions. A more general pic-
ture of the mechanisms of drug suppression is needed to under-
stand and perhaps predict suppressive drug interactions.
Combining suppressive compounds will, in general, be unde-
sirable—typically they require an increased treatment time or
dose with correspondingly increased off-target effects. Howev-
er, such combinations offer potential advantages in the context
of antibiotic resistance, a growing medical concern (Palmer
and Kishony, 2013). It has been suggested that suppressive
combinations decrease the prevalence of resistance to both
drugs in a pair (Yeh et al., 2009). Reciprocal suppression relation-
ships, such that each of two drugs suppresses the effect of the
other, may have an even greater potential to prevent antibiotic
resistance.
Although an improved understanding of suppressive drug in-
teractions has therapeutic implications, no large-scale search541–551, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 541
Figure 1. Types of Interactions between two Drugs
Certain concentrations of drug A and drug B allow growth levels g[drug A] and
g[drug B], respectively. These drugs are considered independent under the
Bliss independence model if their combined effect is the multiplication of the
effects of individual drugs, shown as a black filled circle (g[drug A]3 g[drug B]).
Overlapping blue and red circles represent three possible regions under which
the observed growth may fall, which correspond to three types of drug in-
teractions. Synergy or antagonism occurs when the growth rate under drug
combination is smaller or larger than independence, respectively. Suppression
is an extreme form of antagonism, where the growth rate under drug combi-
nation is higher than the growth rate under [drug A]. In this case, drug B is
defined to suppress drug A. Examples for each interaction type are shown as
growth curves under single drugs and combinations: synergistic interaction of
0.72 mg/ml Staurosporine with 16 mg/ml Tacrolimus, antagonistic interaction of
0.72 mg/ml Staurosporine with 0.6 mg/ml Calyculin A, and suppressive inter-
action with 70 mg/ml Bromopyruvate suppressing 1.26 mg/ml Staurosporine.
For growth curve insets: drug A, drug B, drug A+B observed, and drug A+B
expected growth are depicted in red, blue, dashed blue/red, and black,
respectively.
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carried out. As a tractable experimental model, we examined
chemical compounds with anti-fungal activity (‘‘drugs’’) in
S. cerevisiae. We analyzed data for 220 drug-drug pairs: this
included combinatorial drug sensitivity assays previously re-
ported for 175 pairs (Cokol et al., 2011) but that had not been
previously examined for suppression relationships and 45 pairs
for which combinatorial drug sensitivity was newly performed,
one of which was a verification of a previously reported suppres-
sive drug interaction (Butcher and Schreiber, 2003). Taken
together, our results offer an estimate of the frequency of sup-
pression among drugs, suggest that specific drugs have intrinsic
tendencies to suppress or be suppressed by other drugs, and
begin to describe a mechanistic explanation for selected drug
suppression pairs.
RESULTS
Suppressive Drug Interactions in Literature
We conducted an extensive literature search for suppressive
interactions between anti-fungal chemical compounds. Specif-
ically, we identified MEDLINE abstracts that contained the
names (or synonyms) of two chemicals known to inhibit yeast542 Chemistry & Biology 21, 541–551, April 24, 2014 ª2014 Elseviergrowth (Hillenmeyer et al., 2008) and variations of the word
‘‘suppress’’ (Bandy et al., 2009). We curated more than 1,000
literature abstracts to find reports of suppressive drug inter-
actions between anti-fungal drugs. Our literature search yielded
reports of 30 suppressive drug interactions, of which only four
were interactions with respect to the yeast growth rate pheno-
type (Table S1 available online). All four of these cases involved
one different chemical from the so-called Suppressor of FK506
(SFK) class of compounds. Accordingly, all fourSFK compounds
were reported to suppress growth inhibition by Tac under high-
salt conditions (Butcher and Schreiber, 2003, 2004). Only one
of these SFK drugs (SFK1) was commercially available, and we
experimentally verified that SFK1 suppresses Tac (Figure S1).
Our literature search yielded no previously known reciprocal
suppression relationships within any species.
Finding Suppressive Drug Interactions in Previously
Published Experimental Data
We first re-examined data from a previous study (Cokol et al.,
2011) that measured the growth response of S. cerevisiae at
8 3 8 concentration combinations of 175 drug pairs among 33
drugs. Here, tested drug pairs were selected as positive and
negative predictions for drug synergy. Of the tested drug pairs,
45% came from a ‘‘matrix’’ for which all pairwise combinations
among 13 drugs were tested. We defined growth as the area
under the growth curve (AUC). ‘‘Growth level’’ was defined as
growth relative to the growth in the no-drug condition in each
experiment. The names and abbreviations of drugs used in this
study are given in Table 1. Tables S2 and S3 provide raw cell
density measurements and tables of growth levels, respectively,
for all drug pairs analyzed in this study.
Using these measurements of combinatorial drug concentra-
tion-dependent growth, we searched for drug pairs meeting
each of the three criteria (Figure 1): (1) significant antagonism,
such that growth in response to the drug combination was sig-
nificantly higher than the expected growth under the Bliss
Independence model, that is, higher than the multiplicative
expectation based on growth levels obtained for the two drugs
individually, (2) significant suppression, such that growth in
response to the drug combination was significantly higher than
growth in response to the less-potent drug, and (3) meaningful
strength of suppression, such that the growth level in response
to the drug combination was greater than 10% of the growth
level without any drug present. These criteria defined a less-
potent drug to suppress the more-potent drug. Similarly, recip-
rocal suppression exists by definition if two drugs can suppress
the other’s action at some combination of drug concentrations.
This phenomenon has been hypothesized, but not previously
observed (Yeh et al., 2009).
Of the 175 drug pairs we examined, 53 (30%) passed these
stringent criteria for drug suppression relationships. Of these
53 pairs with suppression relationships, 45 were directional
and eight exhibited reciprocal suppression. Examples of broadly
supported directional suppression (e.g., Bromopyruvate [Bro]
suppresses Staurosporine [Sta]) and reciprocal suppression
(Sta and Myriocin [Myr] suppress each other) are shown in
Figure 2. Importantly, the same criteria applied to a control
data set of 25 self-self drug combinations in which no suppres-
sive relationships are expected (Cokol et al., 2011) found noLtd All rights reserved
Table 1. Drugs Analyzed for Drug-Drug Suppression
Drug Abbreviation Max Dose (mg/ml) Experimental Tests and Suppressive Interactions
1,10-phenanthroline 110 5 AmB, Ben, Bro, Sta
2-deoxy-D-glucose 2DG 250 Sta
5-fluorouracil 5FU 28 Ben, Lat, Pen, Sta, Tac, Ter
6-azauracil 6Az 1,000 AmB, Ben, Bro, Sta
Amphotericin B AmB 0.49 110, 6Az, Ben, Cer, Cet, Dox, Flu, Mic, Naz, Nys, Pen, Phl, Sta, Tac, Ter
Anisomycin Ani 3.5 Ben, Lat, Pen, Sta, Tac, Ter
Aureobasidin A AbA 280 Lit, Wor
Benomyl Ben 28 110, 5FU, 6Az, AmB, Ani, Bro, C3P, Cal, Cer, Cet, Chl, Cis, Cyc, Dyc, Dox,
Fen, Flu, Hal, Lat, Met, Mic, MMS, Myr, Naz, Nys, Pen, Phl, Qmy, Rad, Rap,
Sta, Tac, Ter, Tun
Bromopyruvate Bro 490–1,000a 110, 6Az, Ben, Cal, Cer, Cet, Dox, Dyc, Fen, Flu, Hal, Lat, Mic, Naz, Nys,
Pen, Phl, Rap, Sta, Tac, Ter, Tun
Calyculin A Cal 2.1 Ben, Bro, Dyc, Fen, Hal, Lat, Pen, Rap, Sta, Tac, Ter, Tun
Cantharidin Can 140 Lat, Pen, Sta, Tac, Ter
Carbonyl cyanide
3-chlorophenylhydrazone
C3P 21 Ben, Lat, Pen, Sta, Tac, Ter
Cerulenin Cer 0.335 AmB, Ben, Bro, Sta
Cetylpryidinium Cet 0.8 AmB, Ben, Bro, Sta
Chlorzoxazone Chl 350 Ben, Lat, Pen, Sta, Tac, Ter
Cisplatin Cis 80 Ben, Lat, Sta, Tac, Ter
Clozapine Clo 105 Rad
Cycloheximide Cyc 0.91 Ben, Lat, Pen, Rad, Sta, Tac, Ter
Doxorubicin Dox 11.6 AmB, Ben, Bro, Sta
Dyclonine Dyc 49 Ben, Bro, Cal, Fen, Hal, Lat, Pen, Rap, Sta, Tac, Ter, Tun
Fenpropimorph Fen 1.54 Ben, Bro, Cal, Dyc, Hal, Lat, Pen, Rap, Sta, Tac, Ter, Tun
Fluconazole Flu 10 AmB, Ben, Bro, Sta
Haloperidol Hal 56 Ben, Bro, Cal, Dyc, Fen, Lat, Pen, Rap, Sta, Tac, Ter, Tun
Hygromycin Hyg 7 Lat, Myr, Rad, Rap, Sta
Iodoacetamide Ide 3 Sta
Iodoacetate Ite 500 Sta
Latrunculin B Lat 14 5FU, Ani, Ben, Bro, C3P, Cal, Can, Chl, Cis, Cyc, Dyc, Fen, Hal, Hyg,
Met, MMS, Myr, Pen, Qmy, Rad, Rap, Sta, Tac, Tam, Ter, Tun
Lithium Lit 4,500 AbA, Rad, Rap, Sta, Tac
Methotrexate Met 1,000 Ben, Lat, Pen, Sta, Tac, Ter
Methyl methanesulfonate MMS 175 Ben, Lat, Pen, Sta, Tac, Ter
Miconazole Mic 0.12 AmB, Ben, Bro, Sta
Myriocin Myr 0.350 Ben, Hyg, Lat, Pen, Qnn, Rad, Sta, Tac, Ter
Nystatin Nys 2 AmB, Ben, Bro, Sta
Pentachlorophenol PcP 28 Sta
Pentamidine Pen 70 5FU, AmB, Ani, Ben, Bro, C3P, Cal, Can, Chl, Cyc, Dyc, Fen, Hal, Lat,
Met, MMS, Myr, Qmy, Rad, Rap, Sta, Tac, Ter, Tun
Phleomycin Phl 0.00083 AmB, Ben, Bro, Sta
Quinine Qnn 1,000 Myr, Rad
Quinomycin Qmy 30 Ben, Lat, Pen, Sta, Tac, Ter
Radicicol Rad 56 Ben, Clo, Cyc, Hyg, Lat, Lit, Myr, Pen, Qnn, Rap, Sta, Tac, Ter
Rapamycin Rap 0.0049 Ben, Bro, Cal, Dyc, Fen, Hal, Hyg, Lat, Lit, Pen, Rad, Sta, Tac, Ter, Tun
Sodium azide Naz 25 AmB, Ben, Bro, Sta
Staurosporine Sta 1.26 110, 2DG, 5FU, 6Az, AmB, Ani, Ben, Bro, C3P, Cal, Can, Cer, Cet, Chl,
Cis, Cyc, Dox, Dyc, Fen, Flu, Hal, Hyg, Ide, Ite, Lat, Lit, Met, Mic, MMS,
Myr, Naz, Nys, Pcp, Pen, Phl, Qmy, Rad, Rap, Tac, Tam, Ter, Tun, Wor
(Continued on next page)
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Table 1. Continued
Drug Abbreviation Max Dose (mg/ml) Experimental Tests and Suppressive Interactions
Suppressor of FK506 Sfk 3 Tac
Tacrolimus Tac 110 5FU, AmB, Ani, Ben, Bro, C3P, Cal, Can, Chl, Cis, Cyc, Dyc, Fen, Hal,
Lat, Lit, Met, MMS, Myr, Pen, Qmy, Rad, Rap, Sfk, Sta, Tam, Ter, Tun
Tamoxifen Tam 2.8 Lat, Sta, Tac, Ter
Terbinafine Ter 10.5 5FU, AmB, Ani, Ben, Bro, C3P, Cal, Can, Chl, Cis, Cyc, Dyc, Fen, Hal,
Lat, Met, MMS, Myr, Pen, Qmy, Rad, Rap, Sta, Tac, Tam, Tun
Tunicamycin Tun 0.35 Ben, Bro, Cal, Dyc, Fen, Hal, Lat, Pen, Rap, Sta, Tac, Ter
Wortmannin Wor 280 AbA, Sta
Also given are the three-letter abbreviations used in the figures, the maximum dose used, and a list of all the drug interaction experiments made for
each drug. The last column indicates the suppressed drug (underlined) and the suppressing drug (shown in bold). Each drug was tested in eight
different concentrations, where the lowest concentration is zero, the highest concentration is close toMIC, and increments are evenly spaced between
these extremes. Thus, the lowest concentration for each drug tested is 1/7 of the MIC value, and the next is at 2/7 of MIC, etc.
aBroMICwas reported as 490 mg/ml in a previous study. In this study, we found BroMIC as 1,000 mg/ml and used this MIC value in experiments. For all
other drugs, the MIC variation was less than 2-fold.
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drug suppression assessment.
Yeast Suppressive Drug Interaction Network
We visualized the suppressive relationships we identified as a
network (Figure 3), in which each drug is represented by a
node and each suppressive relationship by a directed edge.
This network has 61 edges between drug nodes among 350 or-
dered pairs (2 3 175 drug pairs). Hence, the fraction of tests in
which one drug suppresses the other is 17%. We note that this
is a conservative estimate, because the drug pairs we have
analyzed thus far were previously selected for drug synergy,
whereas suppression should correspond to antagonism more
frequently than synergy.
For each drug we assessed the ‘‘out-degree’’ (number of
drugs suppressed by the drug of interest) and the ‘‘in-degree’’
(number of drugs that suppress the drug of interest). Interest-
ingly, we observed that the in-degree and out-degree of drugs
is correlated (r = 0.34, p = 0.05). Thus, drugs that were frequently
suppressing were also frequently suppressed. However, we
noticed several exceptions to this weak correlation. For
example, Bro suppressed 4 (33%) of 12 tested drugs but was
not suppressed by any drug. On the other extreme, Sta was
suppressed by 14 (48%) of the 29 drugs with which it was tested;
but it suppressed only one (3%). These observations suggest
that drugs can differ in intrinsic tendencies for suppression
behavior.
We further analyzed the network for ‘‘suppressing hubs’’ or
‘‘suppressed hubs’’— drugs that are intrinsically more likely to
suppress or be suppressed (Supplemental Experimental Proce-
dures). Amphotericin B (AmB), Benomyl (Ben), Bro, Chlorzoxa-
zone (Chl), and Methotrexate (Met) had true discovery rates
greater than 50% (q < 0.5) for being frequent suppressors
(Fisher’s exact test, p = 0.04, 0.01, 0.14, 0.07, 0.07; OR = 7.4,
3.1, 2.5, 4.9, 4.9; q = 0.22, 0.21, 0.46, 0.49, 0.49, respectively).
We found a significant tendency for Sta to be suppressed
(Fisher’s exact test p = 5.7 3 105, OR = 5.4, q = 9.5 3 104)
and a suggestive tendency (q < 0.5) for AmB and Tun to be
suppressed (Fisher’s exact test p = 0.04, 0.14; OR = 7.4, 2.5;
q = 0.22, 0.46, respectively).544 Chemistry & Biology 21, 541–551, April 24, 2014 ª2014 ElsevierDrug Interaction Experiments to Test Suppression Hubs
Because our power to detect significant ‘‘hubs’’ was necessarily
limited by the number of pairs tested for any given drug, we per-
formed additional experimental testing. Specifically, we further
tested four of these drugs —AmB, Ben, Bro, and Sta— for addi-
tional suppression relationships. Each of these four were as-
sessed against a panel of the following ten drugs selected on
the basis of being inexpensive, readily available, and having
diverse mechanisms of action: 1,10-phenanthroline (a metallo-
peptidase inhibitor and potent transcription inhibitor) (Chang
et al., 1990), 6-azauracil (a nucleic acid synthesis inhibitor)
(Exinger and Lacroute, 1992), cerulenin (a fatty acid biosynthesis
inhibitor) (Inokoshi et al., 1994), cetylpyridinium (a cationic sur-
factant) (Hiom et al., 1993), Doxorubicin (a DNA intercalator)
(Patel et al., 1997), Fluconazole and Miconazole (ergosterol
biosynthesis inhibitors) (Abe et al., 2009; Sud and Feingold,
1981), sodium azide (a cytochrome oxidase inhibitor) (Whitney
and Bellion, 1991), Nystatin (a polyene antibiotic) (de Resende
and Alterthum, 1990), and phleomycin (a DNA intercalator)
(Moore, 1989).
For each of these 40 pairwise combinations, we conducted a
drug interaction experiment as described previously (Cokol
et al., 2011). We identified 30 suppressive drug interactions,
including nine reciprocally suppressing drug pairs. The fraction
of suppressing drug interactions in this second data set is
38%, which is greater than the 17% fraction observed in the
initially analyzed published data set. Each of the drug pairs
tested for suppression included one drug exhibiting frequent
suppression behavior in the original data, so that the high
rate of suppression further supports the idea that drugs have
intrinsic tendencies to suppress or be suppressed. The results
of these 40 drug interaction experiments are given in Figure 4
and Table 1.
All experiments together yielded strong support for the idea
that Bro commonly acts as a suppressor (p = 2.0 3 103, OR =
4.1, q = 0.03). Sta, on the other hand, showed a significant
tendency to be suppressed within the combined data set (p =
2.13 104, OR = 3.7, q = 4.43 103). Together, our observations
allow us to suggest Bro as a ‘‘frequently suppressing drug’’ and
Sta as a ‘‘frequently suppressed drug’’. Consistent with each ofLtd All rights reserved
Figure 2. Assessing Suppression and
Reciprocal Suppression
S. cerevisiae cells were grown in an 8 3 8 grid of
drug combinations, where the concentration of
one drug was linearly increased in each axis. The
maximum dose of each drug was chosen close to
its MIC. For each drug concentration combination,
growth measurements (y axis) for 24 hr (x axis) are
depicted. The growth curves corresponding to
drug combinations in which the horizontal drug
suppresses the vertical drug are given in blue, and
the opposite direction of suppression are given in
green. Here, we show two broadly supported
suppression examples we have found among
175 drug pairs tested, where breadth is defined as
the number of combinations in which the sup-
pression phenotype was observed. Suppressive
edges learned from data are shown between
drug names, where the edge width represents the
breadth of suppression.
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(Figure 2).
We wished to further investigate a specific suppressive drug
interaction and focused on the Bro+Sta interaction. Bro has
received clinical attention because of its selectivity against tumor
cells (Bhardwaj et al., 2010; Ganapathy-Kanniappan et al., 2010).
This selectivity is a result of its inhibition of the glycolysis
pathway, which is highly utilized by tumor cells (Pelicano et al.,
2006; Xu et al., 2005). Several cellular targets for Bro have
been previously characterized, such as hexokinase, pyruvate
kinase, and GAPDH (Shoshan, 2012). Sta is an ATP-competitive
kinase inhibitor with Pkc1 as its primary target (Yoshida et al.,
1992).
Chemogenomic Experiments with Bro, Sta, and Bro+Sta
Combination
In order to have a global understanding of the effect of Bro, Sta,
and their combination on S. cerevisiae, we assessed the sensi-
tivity of a genome-wide collection of yeast deletion strains to
these conditions, using the HaploInsufficiency Profiling (HIP)
and homozygous deletion profiling (HOP) technologies (Giaever
et al., 2002; Hillenmeyer et al., 2008; Parsons et al., 2004; Pierce
et al., 2007). Although HIP and HOP data have been previously
obtained for Sta (Hillenmeyer et al., 2008; Lum et al., 2004), no
such experiments have been reported for Bro or Bro+Sta
combination.
We constructed two pools of isogenic yeast diploid deletion
strains with specific molecular barcode tags: (1) 1,106 strains,
where one copy of an essential gene is deleted (for HIP assays)
and (2) 4,590 strains, where both copies of a non-essential gene
are deleted (for HOP assays). Competitive growth of the mutant
pools was carried out in media with four different conditions: (1)
1% DMSO (‘‘Solvent’’), (2) ‘‘BroIC20,’’ Bro at a concentration that
inhibits growth of the parental wild-type strain (BY4743) by 20%
(IC20) (650 mg/ml), (3) ‘‘StaIC20,’’ Sta at its IC20 concentration
(0.7 mg/ml), and (4) ‘‘ComIC20,’’ an IC20 Bro+Sta combination
with a low dose of Bro (200 mg/ml) and high dose of Sta
(1.2 mg/ml). After competitive growth, the abundance of each
strain was measured by microarray hybridization. The sensitivity
score of a strain to a condition was defined as the negative log-Chemistry & Biology 21,arithm of the ratio of strain abundance under the drug condition
relative to strain abundance in the solvent condition (Pierce et al.,
2007). To assess the reproducibility of these HIP and HOP ex-
periments, biological replicate experiments for the BroIC20
condition were performed. The sensitivity scores for two inde-
pendent replicates of the BroIC20 condition had a very high
correlation (r = 0.83, p < 2.23 1016: the default minimum value
in Matlab), indicating the reproducibility of our experimental
results. For BroIC20 experiments, replicate sensitivity scores
were averaged. The sensitivity scores for 5,696 strains obtained
during these experiments are represented in Figure 5 and pro-
vided in Table S4.
We defined a deletion strain to be sensitive to a condition if
its sensitivity score was greater than two (corresponding to a
2-fold depletion), in accordance with previous genome-wide
chemogenomic studies (Hillenmeyer et al., 2008; Hoon et al.,
2011; Pierce et al., 2007). Among 1,106 heterozygous deletion
strains, we found two strains that were specifically sensitive to
BroIC20 treatment (termed ‘‘Bro-protective genes’’ hereafter, as
mutants in these genes are more sensitive): acs2D/ACS2 and
erg10D/ERG10 (Figure 5). Acs2 (acetyl-coA synthetase) cata-
lyzes the transformation of acetate to acetyl-coA (Van den
Berg and Steensma, 1995). Erg10 converts acetyl-coA to ace-
toacetyl-coA, a requisite for the biosynthesis of mevalonate;
the precursor to sterols and nonsterol isopreniods (Berg et al.,
2010) (Figure 5). It is notable that the only two Bro-protective
genes we identified encode adjacent enzymes in the yeast
metabolic network (Caspi et al., 2013). The two reactions corre-
sponding to the two Bro-protective genes are each critical for
ketogenesis, which is likely to play a role when glycolysis is in-
hibited (Marsh et al., 2008).
We identified 11 heterozygous deletion strains as being
sensitive to StaIC20, but not to BroIC20. Notably, 4 of these 11
StaIC20-sensitive heterozygous deletion strains were previously
found to be sensitive to Sta (pkc1D/PKC1, rho1D/RHO1,
cdc12D/CDC12, and rot1D/ROT1) in another large-scale
chemogenomic study (Lum et al., 2004). We found nine hete-
rozygous deletion strains exhibiting sensitivity specifically to
ComIC20, but not to BroIC20 or to StaIC20. Of the nine ComIC20
specific gene products, five have chromatin remodeling or541–551, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 545
Figure 3. A Network of 61 Suppressive
Drug-Drug Interactions
Nodes represent drugs, and edges represent
suppressive interactions. The width of an edge
represents the breadth of suppression. The nodes
are colored according to the suppression behavior
of each drug. Bright blue and orange areas
correspond to the frequency of ‘‘suppressed’’ and
‘‘suppressing’’ edges for a drug among all in-
teractions against which it was tested. Similarly,
light blue and white areas correspond to the fre-
quency of ‘‘not suppressed’’ and ‘‘not suppress-
ing’’ edges for a drug among all interactions
against which it was tested. The three-letter ab-
breviations for each drug are given in Table 1.
Chemistry & Biology
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Cdc39) (Szerlong et al., 2003; Titus et al., 2010).
Among 4,960 homozygous deletion strains tested, we found
106, 144, and 245 strains that were sensitive to BroIC20, StaIC20,
and ComIC20, respectively. In order to understand cellular func-
tions that are protective in these conditions, we carried out a
functional enrichment analysis (Berriz et al., 2009). Seven of
the top ten functions protective against BroIC20 involved protein
kinase cascades andMAPK signaling pathways (Bhardwaj et al.,
2010). For StaIC20, nine of the top ten protective functions
involved biosynthetic processes. For 120 genes whose deletion
confers sensitivity to ComIC20, but not to either BroIC20 or StaIC20
(Figure 5), we found only nine enriched protective functions, six
of which involved regulation of transcription by one of various
carbon sources.
Taken together, the chemogenomic experiments provided
insight into the mechanisms of Bro and Sta individually. How-
ever, they did not immediately yield clear explanations for the
suppression relationship between Bro and Sta.
Drug Co-Aggregation Experiments
One potential source of an observed suppression relationship is
the effect of one compound on the other’s solubility (Feng and
Shoichet, 2006). To investigate if Bro+Sta combination had a
higher level of aggregation than either Bro or Sta alone, we
conducted dynamic light scattering (DLS) experiments and
estimated the mean radius of aggregates in each condition
(Supplemental Experimental Procedures) (Coan and Shoichet,
2008). Each drug was prepared at its reported minimum inhibi-
tory concentration (MIC) in media/solvent to mimic experimental
conditions for drug interaction testing. We found no aggregate
formation under any of these conditions.
In order to test our aggregate hypothesis further, wemeasured
aggregate formation for nine additional drug pairs with observed
suppression (Bro+Hal, Bro+Sta, Bro+Rap, Bro+Tac, Dyclonine
[Dyc]+Fenpropimorph [Fen], Dyc+Tunicamycin [Tun], Fen+
Terbinafine [Ter], Fen+Tun, Haloperidol [Hal]+Tun, and Rap+
Tac). Among these pairs, we observed no case in which546 Chemistry & Biology 21, 541–551, April 24, 2014 ª2014 Elsevier Ltd All rights reserveddrugs aggregated in combination without
aggregating individually. Similar to Bro+
Sta, drugs formed no aggregates either
individually or in combination with Bro+
Rap, Fen+Ter, and Fen+Tun (Table S6).For the remaining six suppressive drug pairs, the aggregation
observed for the combination was not substantially different
from the maximum observed aggregation for either drug
measured alone. For drugs with high individual aggregation
(Dyc, Hal, and Tac), we conducted further DLS measurements
using lower concentration combinations of drugs to ensure there
was no masking of combined aggregation effects (Table S7). In
all cases, we saw no impact from the presence of one drug on
the solubility of the other and therefore no support for coaggre-
gation as the basis of these ten suppressive interactions.
Drug Interaction Experiments of Sta and a Panel
of Glycolysis Inhibitors
We wished to investigate whether Bro’s tendency to suppress
stemmed from its known activity as a glycolysis inhibitor. To
test whether Bro suppresses Sta via glycolysis inhibition, we
tested Sta’s pairwise interaction with glycolysis inhibitors
2-deoxy-D-glucose (2DG), Iodoacetate (Ite), Iodoacetamide
(Ide) (Figure 6A), and Pentachlorophenol (Pcp) (Figure S7), an
inhibitor of the oxidative phosphorylation process that is also
expected to deplete cellular ATP levels (Schmidt and Dringen,
2009). We observed that Ite and Pcp were the only two drugs
that suppressed Sta, so that there was no apparent correlation
between glycolysis inhibition and Sta suppression.
Interestingly, although both Bro and 2DG are reported to
inhibit glycolysis by targeting hexokinase (Bhardwaj et al.,
2010), only Bro suppressed Sta. This could potentially be ratio-
nalized by the existence of other cellular targets for Bro, such
as pyruvate kinase and GADPH (Ganapathy-Kanniappan et al.,
2009). However, the observation that Ite suppressed, whereas
Ide did not, was less expected, given that these two glycolysis
inhibitors are structurally similar and both are known to be
cysteine peptidase inhibitors (Aitken and Learmonth, 1996). In
this context, we recognized that among the five ATP-depleting
drugs described above, those that suppressed Sta are weak
acids (Bro, Ite, and PcP), whereas the others are not (2DG and
Ide). This corresponded to a suggestive enrichment of acidic
compounds to suppress Sta (Fisher’s exact Test, p = 0.10).
Figure 4. Further Suppression Tests of Four
Drugs against a Panel of Ten Drugs
(A) Experimental results. Drug pairs were com-
bined in 8 3 8 matrices as described in Figure 2.
Significant suppressive interactions between
drugs are shown with green or blue rectangles,
where suppression direction is indicated on the
lower left.
(B) Network representation of results of additional
drug suppression tests. Nodes represent drugs,
and edges represent suppressive interactions.
Edge width and node coloring according to the
suppression behavior of each drug are as
described for Figure 3. The three-letter abbrevia-
tions for each drug are given in Table 1.
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by Bro underlies its suppression of Sta.
Suppression of Sta by Bro Is Explained by Bro Acidity
To test this hypothesis, we carried out several experiments: first,
we found that, at the MIC dose of Bro (1 mg/ml), the growth envi-
ronment pH decreased by approximately 0.5 (from 6.5 to 6.0).
Second, we confirmed that lowering pH by 0.5 had no effect
on yeast growth rate as established in the literature (Orij et al.,
2012). Third, we found that a 0.5 decrease of pH induced an
increase of Sta’s MIC (i.e., suppressing Sta) (Figure 6B) and
uncovered previous reports of this phenomenon (Yoshida and
Anraku, 2000). This effect is discernible even at a pH change of
0.05, which corresponds to the acidity change that is induced
by 10%MIC of Bro. Fourth, we found that the suppressive inter-
action between Bro and Sta is lost when the media is buffered to
6.5 using NaPO4 buffer (Figure 6C). Fifth, we observed that for
the Sta dose that has some inhibitory effect at high pH, the
growth curve obtained in acidic media is indistinguishable from
the no-drug growth curve. Finally, we observed that Sta’s anti-
fungal activity does not change with prior exposure to acidity.
Taken together, these observations suggest that Bro has two
discernible effects. The primary effect is glycolysis inhibition,
which reduces yeast growth directly.Bro has a secondary effect:
media acidification. The magnitude of the pH change caused by
Bro at its MIC has no discernable effect on yeast growth but can
relieve the detrimental effects of Sta.
In order to further understand this phenomenon, we
searched for genetic interactions between Sta-protective genes
and genes for which mutation causes a change in cytosolic pH
(pHc) (Orij et al., 2012). Interestingly, the Sta-protective gene
ARP4 (encoding nuclear actin-related protein) has 14 reported
negative genetic interactions with pHc genes (for which
deletions confer an increase in cytosolic pH) in the BioGRID
Interaction database (Chatr-Aryamontri et al., 2013). In con-Chemistry & Biology 21, 541–551, April 24, 2014trast, we failed to find genetic interac-
tions between Bro- and Sta-protective
genes. Although this represents an inter-
esting avenue for future investigation of
the pH-dependence of Sta, we wished
to focus on the extent to which pH
could explain the suppression network
beyond Bro.For this, we checked the pH impact on the MIC of eight addi-
tional drugs for which all pairwise suppression relationships had
been tested: Ben, Hal, Latrunculin B (Lat), Pentamidine (Pen),
Rap, Sta, Ter, and Tun. No drug other than Bro caused a pH
change in the growth medium. Hence, none of the suppressive
interactions between these eight drugs are likely to be caused
by acidification of the growth media.
To assess whether the pH impact of Bro explained its sup-
pressing effects beyond Sta, we determined the MIC of nine
drugs (Bro and the eight assessed in the preceding paragraph),
both in normal and acidic media. The raw data for these ex-
periments are given as Table S5. ForHal, Rap, and Tac, the three
Bro-suppressed drugs within this set of nine drugs (Figure 3),
acidic media increased the MIC (Figure 6D). Interestingly, the
known targets of these three drugs (Erg2, Tor1, and Cnb1,
respectively) have 19 negative genetic interactions with genes
whose deletion increases cytoplasmic pH. Moreover, all these
targets have a negative genetic interaction with VMA11, an
ATPase involved in proton transport in yeast (Hirata et al., 1997).
These observations suggest the possibility that acidity modifies
the cellular concentration of these drugs by affecting drug
transporters. Decrease of pH also suppressed (i.e., increased
the MIC) of four other drugs within the set of nine tested—Lat,
Pen, Ter, and Tun (Figure 7D), although the effects were subtle
for Ter and Tun. Interestingly, acidity increased the efficacy of
Ben (Figure 6D). We had previously observed no evidence that
Bro interactswith thesedrugs (Cokol et al., 2011). These apparent
conflicts suggest that, for most drug pairs, Bro’s more direct
biological effect is overriding any pH-mediated effects.
DISCUSSION
Here, we systematically analyzed suppression relationship be-
tween drug pairs. We tested 220 drug pairs for suppression:
175 pairs via an analysis of data that had been previouslyª2014 Elsevier Ltd All rights reserved 547
Figure 5. Genome-wide Sensitivity Assess-
ment for Yeast Deletion Strains against
Bromopyruvate (BroIC20), Staurosporine
(StaIC20), and Their Combination (COMIC20)
In the left panel, sensitivity scores for 4,960 strains,
in which both copies of a non-essential gene have
been deleted, are shown as black circles (HOP).
Sensitivity scores for 1,106 strains, in which one
copy of an essential gene has been deleted, are
shown as red circles (HIP). For visibility, the sizes
of the circles are proportional to the absolute value
of the sensitivity scores. In each experiment,
strains are ordered by the alphabetical order of
the systematic name of the deleted gene(s). On the
right of each experiment, the distribution of the
sensitivity scores are shown by magenta fre-
quency distributions, indicating that a large ma-
jority of deletion strains do not show a growth
change. The right panel is a Venn diagram repre-
sentation of the sensitive strains. Black and red
numbers correspond to homozygous or hetero-
zygous deletion strains, respectively.
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44 additional pairs with unknown suppression relationships
examined experimentally for this study, and one pair previously
reported to be suppressive (confirmed here). Collectively, we
found 93 directed drug pairs to exhibit suppressive drug inter-
actions and an overall drug suppression frequency of 17%
(considering only pairs not tested on the basis of suppression
behavior). Based on the extensive literature survey we carried
out for this study, we collectively expanded our knowledge of
growth suppression relationships between anti-fungal com-
pounds by a factor of 23.
We provided evidence that some drugs have intrinsic ten-
dencies to suppress or be suppressed. Thus, drug suppression
frequency likely depends on the drugs and drug pairs tested. In
total, we report 17 reciprocally suppressive drug interactions.
Although drug interactions of this type have been hypothesized
(Yeh et al., 2009), to the best of our knowledge, reciprocal sup-
pression has not been previously reported within any species.
We tested whether drug suppression can arise due to coag-
gregation of two drugs by comparing the aggregate sizes in
individual drugs and combinations. We observed no relationship
between coaggregation and drug suppression for all ten pairs
among the nine drugs examined. In addition, we observed that
some drugs formed aggregates at the doses at which they
inhibited yeast growth. Because drugs in aggregates behave
differently than in solution (Coan and Shoichet, 2008), a more
complete understanding of the aggregation levels of drugs could
further our understanding of drug interactions.
From an analysis of the drug suppression network, we iden-
tified Bro as frequently suppressing and Sta as frequently sup-
pressed. Consistent with each of these trends, we had observed
that Bro strongly suppresses Sta. We conducted chemoge-
nomic experiments with Bro and Sta individually and with a
combination in which suppression is observed. Our results for
Sta were in agreement with previous studies, indicating Pkc1
as a major target and several biosynthetic processes as protec-
tive functions, including steroid and ergosterol synthesis. The548 Chemistry & Biology 21, 541–551, April 24, 2014 ª2014 Elseviertendency of Sta to be suppressed by many drugs (a significant
phenomenon even where suppression by Bro is excluded from
the network) may be explained by the fact that many drugs
induce a stress response (Fulda et al., 2010), which may cause
a decrease of biosynthetic processes shown to be protective
of Sta activity.
As no previous chemogenomic study was conducted for Bro,
our chemogenomic studyof Bro is a genome-wide effect analysis
for this compound, which is currently under investigation as a
chemotherapeutic (Shoshan, 2012). Among 1,106 heterozygous
deletions, we identified only two genes (acetyl-CoA-synthetase
and acetoacetyl-CoA-thiolase) for which deletion confers sensi-
tivity to Bro. Interestingly, both of these genes encode enzymes
impinging on acetyl-CoA metabolism, both carrying out reac-
tions essential during ketogenesis. A reliance on ketogenesis in
the presence of Bro supports reports in humans of a synergy in
the treatment of astrocytoma between glycolysis inhibitors and
a ketogenic diet (Galluzzi et al., 2013) (Marsh et al., 2008).
We foundstrong evidence that the tendency ofBro to suppress
is due to media acidification. Indeed, Bro does not suppress
Sta in pH-buffered media. With further experimentation, we
found that Bro’s suppression of Hal, Rap, and Tac could also
be explained by change in acidity. We also found that the
targets of these drugs have a negative genetic interaction with
VMA11, an ATPase involved in proton transport in yeast (Hirata
et al., 1997). A previous study has found that Sta is exported
from the cytosol by H+/drug antiporters (Yoshida and Anraku,
2000). These observations suggest that acidity modifies the
cellular concentration of these drugs via effecting drug
transporters. We found no evidence that pH effects contributed
to the observed suppression network beyond Bro. Furthermore,
the Bro-protective genes identified by chemogenomic profiling
are presumably unrelated to its acidity, given that the 0.5 pH
change causedbyBro has nodiscernable growth effect on yeast.
Our finding that Bro suppresses Sta by acidifying the extra-
cellular media suggests that Bro has two discernible effects: a
primary effect (glycolysis inhibition, which inhibits cell growth)Ltd All rights reserved
Figure 6. Drug Sensitivity and Interaction
Assays
(A) Drug interaction assays between Staur-
osporine and three glycolysis inhibitors. 2-deoxy-
D-glucose and Iodoacetamide do not suppress
Staurosporine. The regions in which Iodoacetate
suppresses Staurosporine are shown with blue
growth curves.
(B) Growth curves in increasing doses of Staur-
osporine under normal (black) and acidic (red)
media are shown slightly offset for visibility in this
and the next panel. For each drug concentration,
growth measurements (y axis) for 24 hr (x axis) are
depicted. Staurosporine has higher MIC in acidic
media.
(C) Drug interaction assay between Bromopyr-
uvate and Staurosporine under buffered (black) or
unbuffered (red) media. Bromopyruvate does not
suppress Staurosporine under buffered media.
(D) Relationship between growth level (y axis) and
drug dose (x axis) for ten drugs in normal and
acidic media are shown in black and red, respec-
tively. The three-letter abbreviations for drugs are
given in Table 1. Hal, Pen, and Sta have decreased
toxicity, and Ben has increased toxicity under
acidic conditions.
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the pH change is supported by the observation that a pH change
as great as that caused by the MIC concentration of Bro shows
no inhibition of cell growth. In small doses, Bro’s secondary
effect protects the cell from the inhibitory effects of Sta. Thus,
off-target effects of one drugmay protect from the primary effect
of a second drug. These expand the framework of consider-
ations required for further computational or experimental anal-
ysis of drug interactions.
SIGNIFICANCE
Although not every suppression relationship will be clinically
relevant, the observation that 17% of drug pairs not tested
on the basis of suppression behavior exhibited significant
and substantial suppression demonstrates the high pro-
bability that such drug interactions are common and that
many clinically relevant interactions remain to be found.
Here, with a single systematic study of drug suppression
effects, we report 93 suppressive relationships between
antifungals and further suggest a framework for systemati-
cally exploring the mechanisms of drug suppression. This
highlights the value of more extensive study of drug inter-
actions, an important topic at the intersection of pharma-
cology and systems biology.Chemistry & Biology 21, 541–551, April 24, 2014EXPERIMENTAL PROCEDURES
Experimental Tests for Drug Interactions
Latrunculin B, Rapamycin, Staurosporine, and
Tacrolimus were purchased from AG Scientific.
All other drugs were purchased from Sigma. All
drugs were dissolved in DMSO (except bromo-
pyruvate and sodium azide, which were dissolved
in water) and kept at 20C. All experiments
were conducted with S. cerevisiae strains BY4741 or BY4743 or heterozy-
gous/heterozygous deletion strain collections derived from BY4743. Yeast
cells were grown in yeast extract peptone dextrose (YPD) (1% yeast extract,
2% bacto-peptone, and 2% glucose) overnight (OD6005) and diluted to
an OD600 of 0.01 in YPD with the desired drug concentrations controlled
for solvent concentrations (plus 0.2 M NaCl in Tac+SFK experiment).
Cells were grown at 30C for 20–24 hr in 96-well plates in Tecan F200 or
Genios microplate readers, with OD595 readings of cell density recorded
every 15 min. We used the area under growth curve (AUC) of each condition
as a metric of cell growth, after discarding the first ten measurement
points. The growth measurement data obtained during this study are given
as Table S2.
Finding Suppressive Drug-Drug Interactions
For each 8 3 8 grid of drug combinations analyzed, the first column and row
contains linearly increasing concentrations of only one drug. Therefore, they
correspond to the growth rates observed under certain concentration of drugs
A and B, defined as g[A] or g[B]. The remaining rows and columns correspond
to the growth rates observed for 49 different concentration combination of
drugs g[AB]. The growth level in each condition was defined as the area under
growth curve in condition normalized by the area under curve in ‘‘no drug’’
condition. To find suppressive drug interactions, we searched for drug
pairs in which the following conditions are satisfied (1) g[AB] is larger than
g[A] 3 g[B], (2) g[AB] is larger than g[A] or g[B], and (3) g[AB] is larger than
10% of growth in the no drug condition. For each suppressive drug-drug inter-
action, the less-potent drug was defined to suppress the more-potent drug.
The matrices of growth levels and suppressive drug interactions are given as
Table S3. For error model and enrichment analysis, see the Supplemental
Experimental Procedures.ª2014 Elsevier Ltd All rights reserved 549
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S. cerevisiae deletion strains were grown in pools competitively in the pres-
ence of chemicals. One pool contains 1,106 heterozygous deletions strains
deleted for one copy of the essential genes, which identifies chemical targets
through HaploInsufficiency Profiling (HIP). The other pool contains 4,590
homozygous deletions strains deleted for both copies of the non-essential
genes, which identifies genes involved in buffering the chemical target path-
way through homozygous deletion profiling (HOP). Both pools share the
same BY4743 genetic background, and each strain is specifically barcoded.
Five HIPHOP experiments were performed at 20% inhibition levels of Bro-
mopyruvate (two replicates), Staurosporine, a combination of the two drugs
in which suppression has been shown to occur. All yeast cultures started at
an initial OD595 of 0.0625 in the presence of each drug and were grown with
a Tecan F200 microplate reader (Tecan Systems) at 30C with orbital shaking.
OD595 readings were taken every 15 min for the duration of the experiments.
The homozygous deletions strains pool was grown for five generations,
whereas the heterozygous deletions strains pool was grown for 20 genera-
tions. The homozygous and heterozygous pools for each drug treatment
were combined together at an equal amount, and genomic DNA was ex-
tracted. PCR was performed on the genomic DNA to amplify the specific
barcodes associated with deletion strains. The barcodes were then hybridized
to a TAG4 microarray with the complementary sequences of the barcodes.
All drug HIPHOP experiments results were normalized against the DMSO
experiment.Dynamic Light Scattering
Drug solutions were made to 100 times the final concentrations in DMSO
(bromopyruvate in water). Stocks were diluted 10-fold into filtered YPD and
vortexed 10 s. Final samples were made by combining 10 ml of each drug-
YPD stock, adding 80 ml filtered YPD, and vortexing 10 s. Measurements
were made at room temperature using a DynaPro MS/X (Wyatt Technology)
with a 55 mW laser at 826.6 nm. The laser power was 100%, and the detector
angle was 90. Samples were run in duplicate.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.02.012.AUTHOR CONTRIBUTIONS
Mu. Cokol and F.P.R. designed the study. Mu. Cokol, Z.B.W., K.Y., S.L., D.C.,
B.M., A.D., A.G., and Me. Cokol conducted the experiments. Mu. Cokol,
Z.B.W., K.Y., M.T., A.D., M.A., S.C., G.G., I.I., C.N., B.S., and F.P.R. analyzed
the data. Mu. Cokol, Z.B.W., B.M., and R.R.-E. conducted the literature anal-
ysis. Mu. Cokol, Z.B.W., K.Y., M.T., and F.P.R. wrote the paper.ACKNOWLEDGMENTS
We thank the lab of C. Boone for providing access to their TecanGeniosMicro-
plate readers for experiments. Mu. Cokol was supported by an FP7 Marie
Curie IRG grant (268440), the Scientific and Technological Research Council
of Turkey (110S209 and 111S126), and the Turkish Academy of Sciences
GEBIP Programme. M.T. was supported by the National Institutes of Health
(NIH HG004098). C.N. was supported by the Canadian Institutes of Health
(MOP-81340) and a National Institutes of Health grant from the National
Human Genome Research Institute (HG003317). F.P.R. was supported by
the Canada Excellence Research Chairs Program and a Canadian Institute
for Advanced Research Fellowship.
Received: October 20, 2013
Revised: January 26, 2014
Accepted: February 7, 2014
Published: April 3, 2014550 Chemistry & Biology 21, 541–551, April 24, 2014 ª2014 ElsevierREFERENCES
Abe, F., Usui, K., and Hiraki, T. (2009). Fluconazole modulates membrane
rigidity, heterogeneity, and water penetration into the plasma membrane in
Saccharomyces cerevisiae. Biochemistry 48, 8494–8504.
Aitken, A., and Learmonth, M. (1996). Carboxymethylation of cysteine using
iodoacetamide/iodoacetic acid. In The Protein Protocols Handbook, J.M.
Walker, ed. (Totowa, NJ: Humana Press), pp. 339–340.
Bandy, J., Milward, D., and McQuay, S. (2009). Mining protein-protein interac-
tions from published literature using Linguamatics I2E. MethodsMol. Biol. 563,
3–13.
Berg, J.M., Tymoczko, J.L., and Stryer, L. (2010). Biochemistry. (New York:
W.H. Freeman & Company).
Berriz, G.F., Beaver, J.E., Cenik, C., Tasan, M., and Roth, F.P. (2009). Next
generation software for functional trend analysis. Bioinformatics 25, 3043–
3044.
Bhardwaj, V., Rizvi, N., Lai, M.B., Lai, J.C.K., and Bhushan, A. (2010).
Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating
its signaling and energetics. Anticancer Res. 30, 743–749.
Bierer, B.E., Mattila, P.S., Standaert, R.F., Herzenberg, L.A., Burakoff, S.J.,
Crabtree, G., and Schreiber, S.L. (1990). Two distinct signal transmission
pathways in T lymphocytes are inhibited by complexes formed between an
immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA 87,
9231–9235.
Bollenbach, T., Quan, S., Chait, R., and Kishony, R. (2009). Nonoptimal micro-
bial response to antibiotics underlies suppressive drug interactions. Cell 139,
707–718.
Butcher, R.A., and Schreiber, S.L. (2003). A small molecule suppressor of
FK506 that targets the mitochondria and modulates ionic balance in
Saccharomyces cerevisiae. Chem. Biol. 10, 521–531.
Butcher, R.A., and Schreiber, S.L. (2004). Identification of Ald6p as the target
of a class of small-molecule suppressors of FK506 and their use in network
dissection. Proc. Natl. Acad. Sci. USA 101, 7868–7873.
Caspi, R., Altman, T., Billington, R., Dreher, K., Foerster, H., Fulcher, C.A.,
Holland, T.A., Keseler, I.M., Kothari, A., Kubo, A., et al. (2013). The MetaCyc
database of metabolic pathways and enzymes and the BioCyc collection
of Pathway/Genome Databases. Nucleic Acids Res. 36 (Database issue),
D623–D631.
Chang, Y.H., Teichert, U., and Smith, J.A. (1990). Purification and character-
ization of a methionine aminopeptidase from Saccharomyces cerevisiae.
J. Biol. Chem. 265, 19892–19897.
Chatr-Aryamontri, A., Breitkreutz, B.J., Heinicke, S., Boucher, L., Winter, A.,
Stark, C., Nixon, J., Ramage, L., Kolas, N., O’Donnell, L., et al. (2013). The
BioGRID interaction database: 2013 update. Nucleic Acids Res. 41
(Database issue), D816–D823.
Coan, K.E.D., and Shoichet, B.K. (2008). Stoichiometry and physical chemistry
of promiscuous aggregate-based inhibitors. J. Am. Chem. Soc. 130, 9606–
9612.
Cokol, M., Chua, H.N., Tasan, M., Mutlu, B., Weinstein, Z.B., Suzuki, Y.,
Nergiz, M.E., Costanzo, M., Baryshnikova, A., Giaever, G., et al. (2011).
Systematic exploration of synergistic drug pairs. Mol. Syst. Biol. 7, 544.
de Resende, M.A., and Alterthum, F. (1990). Effect of nystatin, amphotericin
B and amphotericin B methyl ester on Saccharomyces cerevisiae with
different lipid composition. Mycopathologia 112, 165–172.
Exinger, F., and Lacroute, F. (1992). 6-Azauracil inhibition of GTP biosynthesis
in Saccharomyces cerevisiae. Curr. Genet. 22, 9–11.
Farha, M.A., and Brown, E.D. (2010). Chemical probes of Escherichia coli
uncovered through chemical-chemical interaction profiling with compounds
of known biological activity. Chem. Biol. 17, 852–862.
Feng, B.Y., and Shoichet, B.K. (2006). Synergy and antagonism of promiscu-
ous inhibition in multiple-compound mixtures. J. Med. Chem. 49, 2151–2154.
Fridell, J.A., Jain, A.K.B., Patel, K., Virji, M., Rao, K.N., Fung, J.J., and
Venkataramanan, R. (2003). Phenytoin decreases the blood concentrationsLtd All rights reserved
Chemistry & Biology
Combinatorial Chemistry/Therapeuticsof sirolimus in a liver transplant recipient: a case report. Ther. Drug Monit. 25,
117–119.
Fugh-Berman, A. (2000). Herb-drug interactions. Lancet 355, 134–138.
Fulda, S., Gorman, A.M., Hori, O., and Samali, A. (2010). Cellular stress re-
sponses: cell survival and cell death. Int. J. Cell Biol. 2010, 214074.
Galluzzi, L., Kepp,O., Vander Heiden,M.G., and Kroemer, G. (2013). Metabolic
targets for cancer therapy. Nat. Rev. Drug Discov. 12, 829–846.
Ganapathy-Kanniappan, S., Geschwind, J.-F.H., Kunjithapatham, R., Buijs,
M., Vossen, J.A., Tchernyshyov, I., Cole, R.N., Syed, L.H., Rao, P.P., Ota,
S., and Vali, M. (2009). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death.
Anticancer Res. 29, 4909–4918.
Ganapathy-Kanniappan, S., Vali, M., Kunjithapatham, R., Buijs, M., Syed, L.H.,
Rao, P.P., Ota, S., Kwak, B.K., Loffroy, R., and Geschwind, J.F. (2010). 3-bro-
mopyruvate: a new targeted antiglycolytic agent and a promise for cancer
therapy. Curr. Pharm. Biotechnol. 11, 510–517.
Giaever, G., Chu, A.M., Ni, L., Connelly, C., Riles, L., Ve´ronneau, S., Dow, S.,
Lucau-Danila, A., Anderson, K., Andre´, B., et al. (2002). Functional profiling of
the Saccharomyces cerevisiae genome. Nature 418, 387–391.
Hillenmeyer, M.E., Fung, E., Wildenhain, J., Pierce, S.E., Hoon, S., Lee, W.,
Proctor, M., St Onge, R.P., Tyers, M., Koller, D., et al. (2008). The chemical
genomic portrait of yeast: uncovering a phenotype for all genes. Science
320, 362–365.
Hiom, S.J., Furr, J.R., Russell, A.D., and Dickinson, J.R. (1993). Effects of
chlorhexidine diacetate and cetylpyridinium chloride on whole cells and
protoplasts of Saccharomyces cerevisiae. Microbios 74, 111–120.
Hirata, R., Graham, L.A., Takatsuki, A., Stevens, T.H., and Anraku, Y. (1997).
VMA11 and VMA16 encode second and third proteolipid subunits of the
Saccharomyces cerevisiae vacuolar membrane H+-ATPase. J. Biol. Chem.
272, 4795–4803.
Hoon, S., Gebbia, M., Costanzo, M., Davis, R.W., Giaever, G., and Nislow, C.
(2011). A global perspective of the genetic basis for carbonyl stress resistance.
G3 (Bethesda) 1, 219–231.
Inokoshi, J., Tomoda, H., Hashimoto, H., Watanabe, A., Takeshima, H., and
Omura, S. (1994). Cerulenin-resistant mutants of Saccharomyces cerevisiae
with an altered fatty acid synthase gene. Mol. Gen. Genet. 244, 90–96.
Leha´r, J., Krueger, A.S., Avery, W., Heilbut, A.M., Johansen, L.M., Price, E.R.,
Rickles, R.J., Short, G.F., 3rd, Staunton, J.E., Jin, X., et al. (2009). Synergistic
drug combinations tend to improve therapeutically relevant selectivity. Nat.
Biotechnol. 27, 659–666.
Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S.,
Hinshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., et al. (2004).
Discovering modes of action for therapeutic compounds using a genome-
wide screen of yeast heterozygotes. Cell 116, 121–137.
Marsh, J., Mukherjee, P., and Seyfried, T.N. (2008). Drug/diet synergy for
managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the
restricted ketogenic diet. Nutr. Metab. (Lond) 5, 33.
Moore, C.W. (1989). Cleavage of cellular and extracellular Saccharomyces
cerevisiae DNA by bleomycin and phleomycin. Cancer Res. 49, 6935–6940.
Ngo, B.T., Pascoe, M., and Khan, D. (2011). Drug interaction between rifam-
picin and sirolimus in transplant patients. Saudi J. Kidney Dis. Transpl. 22,
112–115.
Orij, R., Urbanus, M.L., Vizeacoumar, F.J., Giaever, G., Boone, C., Nislow, C.,
Brul, S., and Smits, G.J. (2012). Genome-wide analysis of intracellular pHChemistry & Biology 21,reveals quantitative control of cell division rate by pH(c) in Saccharomyces
cerevisiae. Genome Biol. 13, R80.
Palmer, A.C., and Kishony, R. (2013). Understanding, predicting and manipu-
lating the genotypic evolution of antibiotic resistance. Nat. Rev. Genet. 14,
243–248.
Parsons, A.B., Brost, R.L., Ding, H., Li, Z., Zhang, C., Sheikh, B., Brown, G.W.,
Kane, P.M., Hughes, T.R., and Boone, C. (2004). Integration of chemical-
genetic and genetic interaction data links bioactive compounds to cellular
target pathways. Nat. Biotechnol. 22, 62–69.
Patel, S., Sprung, A.U., Keller, B.A., Heaton, V.J., and Fisher, L.M. (1997).
Identification of yeast DNA topoisomerase II mutants resistant to the antitumor
drug doxorubicin: implications for the mechanisms of doxorubicin action and
cytotoxicity. Mol. Pharmacol. 52, 658–666.
Patsalos, P.N., and Perucca, E. (2003). Clinically important drug interactions in
epilepsy: interactions between antiepileptic drugs and other drugs. Lancet
Neurol. 2, 473–481.
Pelicano, H., Martin, D.S., Xu, R.-H., andHuang, P. (2006). Glycolysis inhibition
for anticancer treatment. Oncogene 25, 4633–4646.
Pierce, S.E., Davis, R.W., Nislow, C., and Giaever, G. (2007). Genome-wide
analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in
pooled cultures. Nat. Protoc. 2, 2958–2974.
Schmidt, M.M., and Dringen, R. (2009). Differential effects of iodoacetamide
and iodoacetate on glycolysis and glutathione metabolism of cultured astro-
cytes. Front. Neuroenergetics 1, 1.
Shoshan, M.C. (2012). 3-Bromopyruvate: targets and outcomes. J. Bioenerg.
Biomembr. 44, 7–15.
Sud, I.J., and Feingold, D.S. (1981). Mechanisms of action of the antimycotic
imidazoles. J. Invest. Dermatol. 76, 438–441.
Szerlong, H., Saha, A., and Cairns, B.R. (2003). The nuclear actin-related pro-
teins Arp7 and Arp9: a dimeric module that cooperates with architectural pro-
teins for chromatin remodeling. EMBO J. 22, 3175–3187.
Titus, L.C., Dawson, T.R., Rexer, D.J., Ryan, K.J., and Wente, S.R. (2010).
Members of the RSC chromatin-remodeling complex are required for main-
taining proper nuclear envelope structure and pore complex localization.
Mol. Biol. Cell 21, 1072–1087.
Van den Berg, M.A., and Steensma, H.Y. (1995). ACS2, a Saccharomyces cer-
evisiae gene encoding acetyl-coenzyme A synthetase, essential for growth on
glucose. Eur. J. Biochem. 231, 704–713.
Whitney, A.B., and Bellion, E. (1991). ATPase activities in peroxisome-prolifer-
ating yeast. Biochim. Biophys. Acta 1058, 345–355.
Xu, R.-H., Pelicano, H., Zhou, Y., Carew, J.S., Feng, L., Bhalla, K.N., Keating,
M.J., and Huang, P. (2005). Inhibition of glycolysis in cancer cells: a novel strat-
egy to overcome drug resistance associated with mitochondrial respiratory
defect and hypoxia. Cancer Res. 65, 613–621.
Yeh, P.J., Hegreness, M.J., Aiden, A.P., and Kishony, R. (2009). Drug inter-
actions and the evolution of antibiotic resistance. Nat. Rev. Microbiol. 7,
460–466.
Yoshida, S., and Anraku, Y. (2000). Characterization of staurosporine-sensitive
mutants of Saccharomyces cerevisiae: vacuolar functions affect staurospor-
ine sensitivity. Mol. Gen. Genet. 263, 877–888.
Yoshida, S., Ikeda, E., Uno, I., and Mitsuzawa, H. (1992). Characterization of
a staurosporine- and temperature-sensitive mutant, stt1, of Saccharomyces
cerevisiae: STT1 is allelic to PKC1. Mol. Gen. Genet. 231, 337–344.541–551, April 24, 2014 ª2014 Elsevier Ltd All rights reserved 551
